Companies · Biotechnology

BioRegenx Inc.

CHATTANOOGA · Biotechnology

Diligence memoA one-page analyst read on BioRegenx Inc. — recommendation, valuation, rhythm, risks.
$798K
Total raised · real
2
Rounds
0.3×
Latest step-up
Top 86%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Jan 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

BioRegenx Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.65× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
  • Issuer reports $1M–$5M revenue while modeled below niche peers.
At-risk
  • Last raise 3.4 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

BioRegenx Inc. is one of 4291 Biotechnology companies tracked from CHATTANOOGA. By capital raised it ranks in the long tail (ahead of 15% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(c)
Reg D exemption
5
Investors (latest)
2021
Year incorporated
2023-01-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MPre-Seed · 2021-07-20 Raised $615K (real) Modeled valuation $18M (est)$615K$18MPre-Seed2021Pre-Seed · 2023-01-18 Raised $183K (real) Modeled valuation $2.1M (est)$183K$2.1MPre-Seed2023+$183KCumulative $798K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$615K · 2021
Pre-Seed extension$183K · 2023

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$2.1M
Base estimate est.
$98K
Conservative case
$10.8M
Upside case
$1.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $17.7M · 2021-07-202021Pre-Seed · modeled $2.1M · 2023-01-182023
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
3.5 yr
Elapsed time used
3.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
18 mo
Avg between rounds
$533K/yr
Capital velocity
4.9 yr
On record since
2021
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$798K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.4× of median
This company$183K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$2.1M
Sector median$64.2M

Raised more than 15% of sector peers (real $). Modeled value above 5% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #128 of 185.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)TissueMill Technologies LLC · Pre-Seed Raised $1.0M · modeled $18.2M (est)Aldebaran Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $16.3M (est)BullFrog AI Holdings, Inc. · Pre-Seed Raised $866K · modeled $15.4M (est)Vesicle Therapeutics Inc. · Pre-Seed Raised $800K · modeled $14.8M (est)TAUC3 Biologics Ltd · Pre-Seed Raised $839K · modeled $14.4M (est)UCHU Biosensors, Inc. · Pre-Seed Raised $828K · modeled $13.1M (est)BackStop Neural, Inc. · Pre-Seed Raised $884K · modeled $12.9M (est)Virocell Biologics Ltd · Pre-Seed Raised $993K · modeled $12.9M (est)PurCell Bio, Inc · Pre-Seed Raised $841K · modeled $12.6M (est)MicroVizual Inc. · Pre-Seed Raised $750K · modeled $12.0M (est)NeuroX Innovations Inc. · Pre-Seed Raised $1.2M · modeled $11.9M (est)NeuroDex Inc · Pre-Seed Raised $1.3M · modeled $11.8M (est)BioRegenx Inc. (this company) Raised $798K · modeled $2.1M (est)BioRegenx Inc.
CompanyStageRaised · realValue · estvs peer med.
TissueMill Technologies LLCPre-Seed$1.0M$18.2M5.66×
Aldebaran Therapeutics, Inc.Pre-Seed$800K$16.3M5.05×
BullFrog AI Holdings, Inc.Pre-Seed$866K$15.4M4.78×
Vesicle Therapeutics Inc.Pre-Seed$800K$14.8M4.60×
TAUC3 Biologics LtdPre-Seed$839K$14.4M4.48×
UCHU Biosensors, Inc.Pre-Seed$828K$13.1M4.07×
BackStop Neural, Inc.Pre-Seed$884K$12.9M4.01×
Virocell Biologics LtdPre-Seed$993K$12.9M4.00×
PurCell Bio, IncPre-Seed$841K$12.6M3.91×
MicroVizual Inc.Pre-Seed$750K$12.0M3.73×
NeuroX Innovations Inc.Pre-Seed$1.2M$11.9M3.69×
NeuroDex IncPre-Seed$1.3M$11.8M3.67×
BioRegenx Inc. this companyPre-Seed$798K$2.1M0.65×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$615K2021-07-20$3.4M$17.7M90%
Pre-Seed$183K2023-01-18$1.0M$2.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$615K2021-07-20
    • First recorded raise — entered as Pre-Seed.
    • 23 investors on this round.
  2. Pre-Seed$183K2023-01-18
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round 3.4× smaller than the prior — bridge or down round.
    • Revenue band moved $5M–$25M → $1M–$5M.
    • Switched to Rule 506(c) (was Rule 506(b)).
    • 5 investors on this round.
Intelligence
2024 ~Q3
Modeled next raise · ~18mo cadence
$183K
Modeled next size est.range $183K$293K
0.3×
Last step-up
$533K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Long5 other2021-07
Hitesh Juneja1 other2023-01
Robert Doran1 other2021-07
Sherri Adams1 other2023-01
William Resides1 other2021-07
Gary Dale Hennerberg2021-07
Gary Hennerberg2023-01
Hans Vink2021-07
Jody Walker2023-01
Joseph S Bird2023-01
Joseph Simmons Bird, Jr.2021-07
Robert S Doran2023-01
Suzanne Bird2023-01
Registry & provenance

BioRegenx Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1877104
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
OpenView Network PVT LTDOther TechnologyPre-Seed$150K$2.2Mnetwork4 shared operators · same stage
Hestia Investments IncBiotechnologyPre-Seed$800K$1.1Msame sector · same stage
Opus KSD, Inc.BiotechnologyPre-Seed$800K$2.1Msame sector · same stage
Vicapsys Life Sciences, Inc.BiotechnologyPre-Seed$800K$2.8Msame sector · same stage
Nok Therapeutics, Inc.BiotechnologyPre-Seed$817K$976Ksame sector · same stage
Orbit Genomics, Inc.BiotechnologyPre-Seed$780K$3.4Msame sector · same stage
Ora Biomedical, Inc.BiotechnologyPre-Seed$820K$4.4Msame sector · same stage
Otologic Technologies, Inc.BiotechnologyPre-Seed$835K$1.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Biorez, Inc.BiotechnologySeries A$89.0M94%
Rebiotix Inc.BiotechnologySeries B$338.0M93%
Biogix, Inc.BiotechnologySeed$88.8M92%
BioNADrx Holdings, Inc.BiotechnologyPre-Seed$747K92%
BioNex Solutions, Inc.BiotechnologySeed$39.7M91%
BioPlx, Inc.BiotechnologySeed$47.8M91%
Bio2 Technologies, Inc.BiotechnologySeries A$16.4M90%
Biosceptre International LtdBiotechnologyPre-Seed$13.1M90%
Frequently asked
How much funding has BioRegenx Inc. raised?
BioRegenx Inc. has raised approximately $798K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is BioRegenx Inc.'s estimated valuation?
Provath's modeled valuation for BioRegenx Inc. is approximately $2.1M (modeled range $98K–$10.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is BioRegenx Inc. at?
BioRegenx Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Jan 18.
What does BioRegenx Inc. do and where is it based?
BioRegenx Inc. operates in the Biotechnology sector, based in CHATTANOOGA.
Explore related

See where BioRegenx Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at BioRegenx Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.